
Modulim (AKA: MI Inc~Modulated Imaging Inc) Profile last edited on: 9/12/2019
CAGE: 47GX5
UEI: UHKMAAYPA486
Business Identifier: Optical imaging solutions for noninvasive assessment of tissue health Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
Location: Single
Congr. District: 45
County: Orange
Congr. District: 45
County: Orange
Public Profile
Previously dba as Modulated Imaging Inc., in the Spring 2019, management changed the firm's name to Modulim and moved to larger facilities. A pioneer in subsurface optical imaging powered by spatial frequency domain imaging (SFDI), the firm is defined by an advanced imaging technique co-invented by the firm senior management, SFDI deciphers the reflection, absorbance, and scattering of light in tissue to more accurately measure key biomarkers for assessing tissue health. The proprietary technology helps clinicians identify compromised circulation and perfusion by measuring microvascular tissue oxygenation and hemoglobin concentration and distribution. This approach is designed to help clinicians identify patients with compromised circulation for earlier intervention having the potential to save thousands of limbs and lives with a major reduction in treatment costs.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
10-14Revenue Range
1M-1.5MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
10-14Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2019 | 2 | NIH | $4,106,618 | |
Project Title: Modulated Imaging: a Wide-Field Optical Imaging Platform for Clinical Research | ||||
2018 | 2 | NIH | $2,187,736 | |
Project Title: The Development of a Low-Cost, Quantitative Skin Imaging Camera | ||||
2017 | 1 | DHA | $146,600 | |
Project Title: Real-time Modulated Imaging for Assessment of Tissue Viability Prior to Skin Grafts | ||||
2017 | 2 | NIH | $1,982,739 | |
Project Title: Modulated Imaging in Comprehensive Assessment of Diabetic Foot Ulcer Development | ||||
2012 | 2 | NIH | $1,407,326 | |
Project Title: Pre-clinical Feasibility Study of Tissue Oxygenation Imager |
Key People / Management
David J Cuccia -- Founder, CEO & CTO
Frederick Ayers -- Director of Finance
Julene Cray -- VP of Business Development
Amaan Mazhar -- VP of Research and Development
Richard Oberreiter -- Coo
Bruce Sargeant -- VP of Engineering
Frederick Ayers -- Director of Finance
Julene Cray -- VP of Business Development
Amaan Mazhar -- VP of Research and Development
Richard Oberreiter -- Coo
Bruce Sargeant -- VP of Engineering